Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AM

The FLT3 inhibitor, taken during chemotherapy and continued as a single agent for up to 3 years, significantly improved survival compared with standard chemotherapy.

Related Keywords

Portugal , Vienna , Wien , Austria , Lisbon , Lisboa , North Carolina , United States , Harry Erba , Duke Cancer Institute , Division Of Hematologic Malignancies , European Hematology Association , Hematologic Malignancies , Cellular Therapy , Hematology Association , Annual Meeting , Medscape Medical , Acute Leukemia , Acute Myeloblastic Leukemia , Hematology , Chemotherapy , Neoadjuvant , Europe , European , Remission ,